10x Genomics Announces Fred Hutch Collaboration; No Change to Fundamental Thesis

What happened

10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single cell and spatial applications in bladder cancer biomarker discovery and acute myeloid leukemia residual disease detection. The news is a minor positive validation of the company's technology but does not address the core issues highlighted in the DeepValue master report. That report rates TXG a potential sell due to flat core product revenue, collapsing instrument sales, and heavy reliance on non-recurring IP settlements to support margins and cash flow. The collaboration is unlikely to generate immediate revenue and may be more of a scientific or marketing initiative than a commercial inflection. Meanwhile, the company faces NIH funding risk on 20-25% of revenue and execution risk from sales reorganization. At a market cap of ~$2.38 billion and negative earnings, the stock trades on future growth expectations rather than current fundamentals.

Implication

Investors should not overreact to this announcement as it does not address the structural challenges facing 10x Genomics. The collaboration may yield long-term benefits if it leads to new applications or products, but the company still needs to demonstrate organic growth in core product revenue. The master report's scenarios suggest a base case implied value of $16, bear case of $12, and bull case of $22, with the current price near the top of that range. Given the collaboration's lack of immediate financial impact, the risk-reward remains skewed to the downside. Investors should wait for clear evidence of accelerating revenue growth and improving margins before reconsidering the bearish stance.

Thesis delta

The thesis remains unchanged: TXG is a potential sell due to flat core product revenue, instrument declines, and reliance on IP settlements. The Fred Hutch collaboration is a minor positive but does not change the fundamental picture. No shift in rating or conviction is warranted.